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Abstract
Background:  The Catechol-O-methyltransferase (COMT) gene contains a functional
polymorphism, Val158Met, that has been found to influence human pain perception. In one study
fibromyalgia was less likely among those with Val/Val genotype.
Methods: In the 1995–97 Nord-Trøndelag Health Study (HUNT), the association between Val/
Met polymorphism at the COMT  gene and chronic musculoskeletal complaints (MSCs) was
evaluated in a random sample of 3017 individuals.
Results: The distribution of the COMT Val158Met genotypes and alleles were similar between
controls and the twelve different chronic MSCs groups. Even when the Met/Met and Val/Met
genotypes were pooled, the distribution of the Val/Val genotype and other genotypes were similar
between controls and the chronic MSCs groups.
Conclusion: In this population-based study, no significant association was found between Val/Met
polymorphism at the COMT gene and chronic MSCs.
Background
Musculoskeletal complaints (MSCs), a major health prob-
lem worldwide [1,2], probably has a multifactorial etiol-
ogy and genetic factors may be involved. Recently, a
relationship between pain sensitivity and a polymor-
phism at codon 158 in the Catechol-O-methyltransferase
(COMT) gene has been found [3]. COMT is an enzyme
which inactivates catecholamines and catechol-contain-
ing drugs, and a substitution of valine (Val) by methio-
nine (Met) affects the activity of the COMT enzyme.
Individuals with the Val/Val genotype have a three- to
fourfold higher activity of the COMT enzyme and reduced
pain sensitivity as compared to those with Met/Met geno-
type [3]. In accordance with this, case-control studies have
found that migraine [4] and fibromyalgia [5] were less fre-
quent among those with the Val/Val genotype.
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In this population-based study performed among unse-
lected adults we evaluated the relationship between Val/
Met polymorphism at the COMT gene and chronic MSCs.
Methods
Study population
Between August 1995 and June 1997, all inhabitants aged
20 years and older in Nord-Trøndelag county in Norway
(n = 92,936) were invited to participate in the Nord-Trøn-
delag Health Survey ("Helseundersøkelsen i Nord-Trøn-
delag"= HUNT). In brief, two questionnaires including >
200 health-related questions were administrated to the
participants. The first questionnaire (Q1) was enclosed
with the invitation letter and delivered during attendance
at the health examination. The second questionnaire (Q2)
was filled in after the examination and returned by mail.
Chronic MSCs
The HUNT study included questions about musculoskel-
etal symptoms adopted from the Standardized Nordic
Questionnaire [6], which has previously been evaluated
and found to give reliable estimates for low back pain [7],
and for upper limb and neck discomfort [6-8]. Informa-
tion about pain in other parts of the body has not been
validated. All participants were asked: "Have you during
the last year continuously for at least 3 months had pain
and/or stiffness in muscles and joints?" Individuals who
answered "yes" were defined as having chronic MSCs and
these were asked to mark the localization of this pain
(neck, shoulders, elbows, wrist/hands, chest/abdomen,
upper back, low back, hips, knees, and/or ankles/feet).
Those who responded "no" to the screening questions
concerning chronic MSCs were defined as controls.
We also identified individuals with "chronic widespread
pain" defined as axial skeletal pain (pain in the neck,
chest/abdomen, upper back or lower back) and pain
above the waist (neck, shoulders, elbows, wrist/hands,
chest/abdomen or upper back) and below the waist
(lower back, hips, knees, or ankles/feet). The participants
were not asked to distinguish between pain in the left and
the right side of the body and, consequently, we could not
use the 1990 American College of Rheumatology (ACR)
definition of chronic widespread pain.
Genotyping of the COMT locus
Blood sampling was done whenever subjects attended,
and details for the procedure and the content of the
HUNT 2 biobank are described elsewhere [9].
DNA for genotyping was extracted from peripheral blood
leukocytes from whole blood or blood clots stored in the
HUNT 2 biobank, using the Puregene kit (Gentra Systems
Inc.) manually or with an Autopure LS (Gentra Systems
Inc.). Laboratory technicians were blinded to the answer
of the question about MSCs. COMT genotypes were deter-
mined using the LightCycler (Roche Diagnostics Scandi-
navia AB, Bromma, Sweden) fluorescence resonance
energy transfer method [10]. Polymerase chain reaction
(PCR) amplifications were performed in 20 μl reactions
on a LightCycler System, using 2 μl genomic DNA and the
LightCycler-FastStart DNA Master Hybridization Probes
kit (Roche Diagnostics Scandinavia AB, Bromma, Swe-
den). PCR primers (Eurogentec, Seraing, Belgium) and
fluorescence labeled probes (PROLIGO, Paris, France)
used are described elsewhere [11]. Based on melting curve
profiles, participants were classified as having Val/Val,
Val/Met, or Met/Met genotypes. Details on PCR and melt-
ing curve conditions are available on request.
Participation
Out of the 92,936 invited individuals, a total of 64,787
subjects (70%) answered the first question about chronic
MSC in Q1. Details of the non-participants are described
elsewhere [7,12,13].
In the HUNT 2 biobank a total of 62,664 DNA samples
are stored. At the time of HUNT 2, participants were not
sufficiently informed about possible genetic DNA-based
research. Therefore, an extensive information campaign
about functional genomic research was performed in
2002. Each surviving adult HUNT 2 participant (n =
61,426) received an information folder and a personal let-
ter asking for re-consent to include genetic research. In
total, 1185 (1.9%) persons withdrew their consent [9,12].
Out of the remaining group of 60,241 participants, COMT
gene polymorphism analyses were performed in a sample
of 3048 individuals. Approximately 70% of these were
selected completely at random, and the remaining 30%
had been randomly selected as age-matched controls to a
diabetic population, and as a consequence, these were
somewhat older than the HUNT population as a whole.
Out of the 3048 individuals, a total of 3017 (98%) sub-
jects also had responded to the questions about chronic
MSCs.
Ethics
The study was approved by the Regional Committee for
Ethics in Medical Research, and by the Norwegian Data
Inspectorate.
Statistical analysis
Differences between continuous variables were tested
with analyses of variance (one-way ANOVA) and dichoto-
mous variables by the chi-square test. Analyses used two-
tailed estimation of significance, and due to multiple
numbers of comparisons, p < 0.01 was considered to be
statistically significance (adjustment with Bonferroni
method). Overall, our sample of 1529 individuals with
chronic MSCs and 1488 controls had power to detect aBMC Musculoskeletal Disorders 2006, 7:40 http://www.biomedcentral.com/1471-2474/7/40
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6% difference in prevalence of chronic MSCs between
genotypes with 95% certainty and 90% power. For the
groups with low number of individuals, e.g. pain in chest/
abdomen, the study had 80% power to detect a 5% differ-
ence in prevalence with 95% certainty.
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 13.0 (SPSS
Inc, Chicago).
Results
The distribution of genotypes among the 3017 individu-
als was in Hardy-Weinberg equilibrium. The demographic
data are shown in Table 1. No significant difference in
gender, age or education level was found between the gen-
otype groups. However, the individuals with known
COMT genotype were significantly older than those with-
out COMT data available (p < 0.05) (Table 1).
In total 629 (45.7%) out of 1375 men and 900 (54.8%)
out of 1642 women reported chronic MSCs. The distribu-
tion of the COMT Val158Met genotypes and alleles were
similar between controls and the twelve types of chronic
MSCs (Table 2). When the Met/Met and Val/Met geno-
types were pooled, the distribution of the Val/Val geno-
type and other genotypes were similar among controls
and all the chronic MSCs groups (data not shown). When
the Val/Val and Met/Val genotypes were pooled, chronic
MSCs tended to be less likely in men with Met/Met poly-
morphism compared with those with other genotypes
(29.4% vs. 34.7%, p = 0.04), especially chronic neck pain
(26.5%, p = 0.03) and chronic pain in elbows (22.7%, p
= 0.03) (Table 3).
Discussion
In this population-based study among 3017 unselected
adults, no clear association between chronic MSCs and
the Val158Met polymorphism at the COMT  gene was
found.
Previously, individuals with the COMT Val/Val genotype
have been found to be less susceptible to pain [3], and in
one study fibromyalgia was less frequent among those
with the Val/Val genotype [5]. However, when pooling
the Met/Met and Val/Met genotypes, the distribution of
the Val/Val genotype and other genotypes were similar
between controls and all the twelve different chronic
MSCs groups. In fact, an opposite tendency was found
among men, since chronic MSCs tended to be less likely
with Met/Met polymorphism compared with those with
other pooled genotypes. In accordance with our results,
Val158Met polymorphism was not associated with neuro-
pathic pain in a Spanish population [14].
The strength of this study was the fact that the COMT gen-
otyping was performed randomly among individuals
from the same unselected and genetically homogenous
white Norwegian population. A genetically homogenous
population reduces the potential for bias in genetic case-
control studies involving mixed ethnicities. There are,
however, limitations that must be taken into account.
Since our estimates were based on data from a random
sample among the 70% of the adult population in Nord-
Trøndelag who responded to the questions about MSCs,
one may question to what degree the results can be gener-
alized. The fact that neither musculoskletal symptoms nor
genetic DNA-based research were the primary objectives
of the study makes interest related participation unlikely.
Less than 2% of the surviving adults in 2002 withdrew
their consent to include genetic research [9,12].
Individuals who reported chronic MSCs were divided into
different groups based on the anatomical location of the
pain. The pain in these different sites probably has various
local causes and mechanisms, and it is a potential limita-
tion of our study that we could not categorize the pain
according to these. Thus, we can not rule out the possibil-
ity of a relationship between Val158Met polymorphism
and more specific causes of chronic MSCs. On the other
hand, since the COMT gene has been thought to play a
role in pain sensitivity in general, one might assume that
it could be important in several different pain conditions.
Our study could not confirm an association between
chronic MSCs and COMT codon 158 polymorphism. Of
course, non-replications raise concerns about power.
However, our sample of 1529 individuals with chronic
MSCs and 1488 controls should have enough power to
Table 1: COMT genotypes related to sex, age, and education.
No COMT genotyping Met/Met Met/Val Val/Val
Characteristics (n = 61,770) (n = 962) (n = 1501) (n = 554)
Sex, female (%) 53.0 53.8 52.5 55.2
Age, mean (SD) 48.9 (17.1) 53.0 (18.3) 52.9 (18.1) 52.2 (18.0)
Years of education
≤ 9  ( % ) 3 64 04 24 0
1 0 – 1 2  ( % ) 4 44 14 14 1
>  1 2  ( % ) 2 01 91 71 9BMC Musculoskeletal Disorders 2006, 7:40 http://www.biomedcentral.com/1471-2474/7/40
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detect a difference in prevalence between genotypes that is
of clinical interest, even for the pain groups with low
number of individuals.
To date, no other functional polymorphisms within the
COMT gene has been linked to chronic MSCs. However,
two other different genetic haplotypes of the COMT gene
have been found to be involved in pain perception in a
recent case-control study [15]. Thus, whether the other
Table 3: Distribution of COMT genotypes (Met/Met and pooled Met/Val or Val/Val) in controls and different chronic MSCs groups 
separated by gender
Men Women
Met/Met Met/Val or Val/Val p Met/Met Met/Val or Val/Val p
Genotypes
Controls (%) 259 34.7 487 65.3 246 33.2 496 66.8
Chronic MSCs (%) 185 29.4 444 70.6 0.04 272 30.2 628 69.8 0.22
Chronic neck pain (%) 58 26.5 161 73.5 0.03 91 29.3 220 70.7 0.25
Chronic shoulder pain (%) 72 28.3 182 71.7 0.07 109 31.4 238 68.6 0.62
Chronic elbow pain (%) 20 22.7 68 77.3 0.03 52 32.1 110 67.9 0.87
Chronic wrist/hand pain (%) 36 27.9 93 72.1 0.16 68 28.9 167 71.1 0.26
Chronic chest/abdomen pain (%) 17 28.3 43 71.7 0.39 37 35.9 66 64.1 0.66
Chronic upper back pain (%) 30 37.5 50 62.5 0.71 63 33.7 124 66.3 0.96
Chronic lower back pain (%) 67 30.7 151 69.3 0.31 87 28.2 221 71.8 0.14
Chronic hip pain (%) 44 28.0 113 72.0 0.13 94 32.1 199 67.9 0.80
Chronic knee pain (%) 46 28.4 116 71.6 0.15 91 30.3 209 69.7 0.42
Chronic ankle/foot pain (%) 40 29.0 98 71.0 0.23 75 28.8 185 71.2 0.23
Chronic widespread pain (%) 60 30.0 140 70.0 0.24 102 30.7 230 69.3 0.47
Table 2: Distribution of COMT genotypes and alleles in controls and different chronic MSCs groups separated by gender
Men Women
Met/Met Met/Val Val/Val Met/Met Met/Val Val/Val
Genotypes
Controls (%) 259 34.7 351 47.1 136 18.2 246 33.2 360 48.5 136 18.3
Chronic MSCs (%) 185 29.4 332 52.8 112 17.8 272 30.2 458 50.9 170 18.9
Chronic neck pain (%) 58 26.5 118 53.9 43 19.6 91 29.3 166 53.4 54 17.4
Chronic shoulder pain (%) 72 28.3 132 52.0 50 19.7 109 31.4 182 52.4 56 16.1
Chronic elbow pain (%) 20 22.7 52 59.1 16 18.2 52 32.1 81 50.0 29 17.9
Chronic wrist/hand pain (%) 36 27.9 71 55.0 22 17.1 68 28.9 118 50.2 49 20.9
Chronic chest/abdomen pain (%) 17 28.3 37 61.7 6 10.0 37 35.9 49 47.6 17 16.5
Chronic upper back pain (%) 30 37.5 32 40.0 18 22.5 63 33.7 99 52.9 25 13.4
Chronic lower back pain (%) 67 30.7 110 50.5 41 18.8 87 28.2 161 52.3 60 19.5
Chronic hip pain (%) 44 28.0 87 55.4 26 16.6 94 32.1 141 48.1 58 19.8
Chronic knee pain (%) 46 28.4 76 46.9 40 24.7 91 30.3 161 53.7 48 16.0
Chronic ankle/foot pain (%) 40 29.0 76 55.1 22 15.9 75 28.8 138 53.1 47 18.1
Chronic widespread pain (%) 60 30.0 103 51.5 37 18.5 102 30.7 170 51.2 60 18.1
Alleles Met Val Met Val
Controls (%) 869 58.2 623 41.8 852 57.4 632 42.6
Chronic MSCs (%) 702 55.8 556 44.2 1002 55.7 798 44.3
Chronic neck pain (%) 234 53.4 204 46.6 348 55.9 274 44.1
Chronic shoulder pain (%) 276 54.3 232 45.7 400 57.6 294 42.4
Chronic elbow pain (%) 92 52.3 84 47.7 185 57.1 139 42.9
Chronic wrist/hand pain (%) 143 55.4 115 44.6 254 54.0 216 46.0
Chronic chest/abdomen pain (%) 71 59.2 49 40.8 123 59.7 83 40.3
Chronic upper back pain (%) 92 57.5 68 42.5 225 60.2 149 39.8
Chronic lower back pain (%) 244 56.0 192 44.0 335 54.4 281 45.6
Chronic hip pain (%) 175 55.7 139 44.3 329 56.1 257 43.9
Chronic knee pain (%) 168 51.9 156 48.1 343 57.2 257 42.8
Chronic ankle/foot pain (%) 156 56.5 120 43.5 288 55.4 232 44.6
Chronic widespread pain (%) 223 55.8 177 44.2 374 56.3 290 43.7Publish with BioMed Central    and   every 
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genetic haplotypes of the COMT  gene have relevance
chronic MSCs remains unclear.
Conclusion
In this population-based study, no significant association
was found between COMT codon 158 polymorphism and
chronic MSCs.
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